Amydis detects molecular biomarkers in the eye

Accessible, affordable, adoptable, designed to fit the clinical workflow

Amydis patent-protected eye tracer formulated to address different markets.

Use imaging technologies and workflows already established in eye care practices.

Molecular biomarker images captured during office visit to power AI-based insights.

Why the eye?

The eye reveals pathologies that lead to vision loss and offers valuable insights into overall health. The eye provides a non-invasive view of cells connected to the brain, making it a window into neurodegeneration. Eye vasculature provides insights into other vascular organ systems such as the heart. Molecular biomarkers in the eye allow for detection of diseases in the earliest stages possible.

Therefore, eye care providers are positioned to become earliest point of healthcare, including becoming healthcare hubs for detecting neurodegenerative and cardiological diseases through the eye.

Why Amydis?

Amydis is a leader in developing ocular tracers to enable breakthrough disease detection and insights. 

Why now?

Digital health technology is advancing at an unprecedented speed.

The eye contains molecular biomarkers linked to multiple diseases of the body.


The molecular biomarker, amyloid beta (Aβ), has been shown to be present in the retina of patients with two neurodegenerative diseases that lead to blindness: glaucoma and age-related macular degeneration.


The molecular biomarker, transthyretin (TTR), typically detected in systemic organs such as the heart, kidney, and liver, has been shown to be present in the front of the eye of patients with TTR systemic amyloidosis.


The molecular biomarkers, amyloid beta and alpha synuclein typically detected in the brain, have been shown to present in the retina of patients with Alzheimer’s disease and Parkinson’s disease.